Yahoo
Tokyo - Delayed Quote JPY

Sysmex Corporation (6869.T)

1,941.50 +12.50 (+0.65%)
At close: October 30 at 3:30:00 PM GMT+9
Chart Range Bar
Loading chart for 6869.T
  • Previous Close 1,929.00
  • Open 1,918.50
  • Bid 1,941.00 x --
  • Ask 1,949.50 x --
  • Day's Range 1,908.50 - 1,958.00
  • 52 Week Range 1,246.00 - 2,025.00
  • Volume 3,747,800
  • Avg. Volume 3,033,373
  • Market Cap (intraday) 1.169T
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) 30.45
  • EPS (TTM) 63.76
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield 40.00 (2.06%)
  • Ex-Dividend Date Mar 30, 2027
  • 1y Target Est 2,139.29

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

www.sysmex.co.jp

10,861

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

6869.T
28.95%
Nikkei 225 (^N225)
25.73%

1-Year Return

6869.T
15.34%
Nikkei 225 (^N225)
23.31%

3-Year Return

6869.T
11.65%
Nikkei 225 (^N225)
106.18%

5-Year Return

6869.T
55.59%
Nikkei 225 (^N225)
119.05%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 130.67B
Earnings 8.69B
Profit Margin 6.65%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
50B
100B
2.0%
4.0%
6.0%
8.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

1,500.00 Low
2,139.29 Average
1,941.50 Current
3,300.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.54%

  • Return on Assets (ttm)

    6.10%

  • Return on Equity (ttm)

    8.34%

  • Revenue (ttm)

    524.95B

  • Net Income Avi to Common (ttm)

    39.59B

  • Diluted EPS (ttm)

    63.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    113.63B

  • Total Debt/Equity (mrq)

    25.41%

  • Levered Free Cash Flow (ttm)

    21.32B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: